Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma by Seidel, Clemens et al.
RESEARCH ARTICLE Open Access
Does age matter? - A MRI study on peritumoral
edema in newly diagnosed primary glioblastoma
Clemens Seidel
1, Nils Dörner
2, Matthias Osswald
1, Antje Wick
1, Michael Platten
1, Martin Bendszus
2 and
Wolfgang Wick
1*
Abstract
Background: Peritumoral edema is a characteristic feature of malignant glioma related to the extent of
neovascularisation and to vascular endothelial growth factor (VEGF) expression.
The extent of peritumoral edema and VEGF expression may be prognostic for patients with glioblastoma. As older
age is a negative prognostic marker and as VEGF expression is reported to be increased in primary glioblastoma of
older patients, age-related differences in the extent of peritumoral edema have been assessed.
Methods: In a retrospective, single-center study, preoperative magnetic resonance imaging (MRI) scans of steroid-
naïve patients (n = 122) of all age groups were analysed. Patients with clinically suspected, radiologically likely or
known evidence of secondary glioblastoma were not included.
Extent of brain edema was determined in a metric quantitative fashion and in a categorical fashion in relation to
tumor size. Analysis was done group-wise related to age. Additionally, tumor size, degree of necrosis, superficial or
deep location of tumor and anatomic localization in the brain were recorded.
Results: The extent of peritumoral edema in patients >65 years (ys) was not different from the edema extent in
patients ≤ 65 ys (p = 0.261). The same was true if age groups ≤ 55 ys and ≥ 70 ys were compared (p = 0.308).
However, extent of necrosis (p = 0.023), deep tumor localization (p = 0.02) and frontal localisation (p = 0.016) of
the tumor were associated with the extent of edema. Tumor size was not linearly correlated to edema extent
(Pearson F = 0.094, p = 0.303) but correlated to degree of necrosis (F = 0.355, p < 0.001, Spearman-Rho) and depth
of tumor (p < 0.001). In a multifactorial analysis of maximum edema with the uncorrelated factors age, regional
location of tumor and degree of necrosis, only the extent of necrosis (p = 0.022) had a significant effect.
Conclusion: Age at diagnosis does not determine degree of peritumoral edema, and tumor localization in the
white matter is associated with greater extent of edema. The area of necrosis is reflective of volume of edema. In
summary, the radiographic appearance of a glioblastoma at diagnosis does not reflect biology in the elderly
patient.
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Background
Peritumoral edema is a characteristic feature of malig-
nant glioma, related to the extent of neovascularisation
and to vascular endothelial growth factor (VEGF)
expression [1-3]. It is well recognized that VEGF is a
major and potent mediator of blood brain barrier distur-
bance and a cause of peritumoral edema [4,5].
Some studies have reported a correlation between VEGF
expression and extent of peritumoral edema [6,7]. Others
show an association of extensive peritumoral edema on
magnetic resonance imaging (MRI) with bad prognosis in
patients with newly diagnosed glioblastoma [8-10].
Additionally, a recent study demonstrated that
increased VEGF expression is more frequent in older
patients with glioblastoma [11].
The aim of our study was to examine whether peritu-
moral edema is more pronounced in elderly patients with
primary glioblastoma. We assessed whether increasing
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glioblastoma with increasing age [12].
Methods and Patient characteristics
Methods
In this retrospective, single-center study, we analyzed
preoperative MRI scans at first (suspected) diagnosis in
two groups of steroid-naïve patients (≤ 65 ys and >65
ys) with primary glioblastoma. The patients were conse-
cutively seen in our center between 2004 and 2010.
Patients with known or radiological evidence of sec-
ondary glioblastoma were excluded. Only 5/122 had
areas suspicious for low-grade tumor but no clinical his-
tory of prior tumor manifestation. For all patients, preo-
perative MRI including native and contrast-enhanced
T1-w and T2-w sequences were available. Analysis was
done on digital images on a workstation (Leonardo, Sie-
mens, Erlangen, Germany).
Necrosis and extent of edema and maximum tumor
size were determined on axial contrast-enhanced T1-
and T2-w MRI images, respectively. When edema exten-
sion was greater in the cranio-caudal direction than in
the axial direction, coronal or sagittal images were used
for edema determination.
To accurately quantify the local extent of maximum
edema, the distance from the outer edge of maximum
edema to the nearest point of contrast enhancing tumor
border was measured in mm as described elsewhere [10].
Contrast-enhanced tumor was used to assess tumor size.
To describe the two-dimensional extent of edema in
relation to tumor size a categorical scoring system was
used, similar to what has been reported by others [9]
(Table 1, Figure 1A-D). A standardized volumetric
approach is not available.
To detect a 30% difference, 61 patients were included
in each group. In a second analysis, to exclude an overlap
of pathophysiological effectsi np a t i e n t sa g e d5 5 - 7 0y s ,
different age limits were set (≤ 55, 55-69, and ≥ 70 ys).
As potential confounders, we assessed: 1) largest tumor
area (in mm
2) on a single slice, 2) superficial or deep loca-
lization in the brain (defined as being predominantly
located in the grey matter for a superficial and deep white
matter for a deep localization), 3) degree of necrosis
(hypointense region on T1-w in the centre of contrast-
enhancing tumor, scored as in Table 1, Figure 1E-H) and
4) regional location of tumor (frontal, pericentral,
temporal, parietooccipital, basal ganglia). To avoid obser-
ver bias, radiological analysis was performed by an experi-
enced neuro-oncologist (C.S.) and referenced by an
independent neuroradiologist (N.D.). Both observers were
blinded for clinical data including patient age.
Patient characteristics
All group characteristics are shown in Table 2. In the
primary data set (age cut-off 65 ys) 61 patients per
g r o u pw e r ei n c l u d e d .T h eg r o u p s≤ 55 ys, 55-69 ys and
≥ 70 ys comprised 42, 41 and 39 patients, respectively.
There was no significant difference in mean tumor area
(p = 0.706, t-test) or degree of necrosis (p = 0.173,
Mann-U-Whitney) between the two groups with age
limit 65 ys. The same applied to the three groups of
patients with the age limits 55 ys and 70 ys (p = 0.140,
ANOVA).
Results
Do older patients with primary glioblastoma exhibit more
peritumoral edema?
Edema extent did not differ significantly between the
age groups. This was consistently shown for the deter-
mination of the maximum extent of edema (p = 0.261,
t-test, Figure 2A) and for the degree of edema as deter-
mined by categorical scoring in relation to tumor size.
The latter showed a trend toward less edema (p = 0.106,
Jonckheere-Terpstra) in patients >65 ys.
When patient groups ≤ 55 ys and ≥ 70 ys were com-
pared, maximum extent of edema did not differ (p =
0.308, t-test, Figure 2B). Edema degree was lower in the
group of older patients but did not reach statistical sig-
nificance (p = 0.133, Jonckheere-Terpstra; data not
shown).
As expected from the above, there was no correlation
between age and maximum extent of edema (Pearson
correlation coefficient: -0.076, p = 0.407, Figure 2C).
Which factors do influence the extent of peritumoral
edema?
Localisation of tumor
Interestingly, there are differences between different
tumor localisations and the maximum peritumoral
edema (p = 0.016; ANOVA, Figure 3A) as well as the
degree of edema (p = 0.042, Krustal-Wallis Test, data not
shown). The largest maximum edema was seen in frontal
Table 1 Grading system of edema and necrosis, (in
analogy to [8])
Grade Edema
0 No edema
1 Minimal edema
2 Edema approximately equal to tumor area
3 Major edema greater than tumor area
Grade Necrosis
0 no necrosis
1 necrosis <25% of tumor area
2 necrosis 25-50% of tumor area
3 necrosis >50% of tumor area
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Page 2 of 8(n = 35) and temporal (n = 35) tumors whereas in other
regions (pericentral [n = 27], parietooocipital [n = 19],
basal ganglia [n = 5]) maximum tumor edema appeared
to be less extensive. Examples are shown in Figure 4
(A frontal, B temporal, C basal ganglia, D parietooccipital).
With Bonferroni corrections there is a strong trend for
larger perifocal edema of frontal tumors compared to
tumors in pericentral or parietoccipital regions (p =
0.054 and 0.057). There were no differences between
tumors in the other regions.
Deeply located, mainly white matter tumors (n = 103)
had a higher maximum edema (p = 0.02, t-test) and also
a higher degree of edema (p = 0.006, Krustal-Wallis)
than superficial, mainly grey matter tumors (n = 19)
( F i g u r e3 B ) .S o m ee x a m p l e sa r es h o w ni nF i g u r e4 E - F .
Superficial tumors were significantly smaller than deep
tumors (p < 0.001, t-test).
Degree of necrosis
Tumors with a higher degree of necrosis were found to
have a higher maximum edema (p = 0.012, ANOVA)
and a higher degree of edema (p = 0.023, Jonckheere-
T e r p s t r a )t h a nt u m o r sw i t hl e s sn e c r o s i s( F i g u r e3 C ) .
Some examples are shown in Figure 4G-H. After Bon-
ferroni correction maximum edema only differed signifi-
cantly between no and >50% necrosis (p = 0.029). No
effect was seen for the edema index.
Degree of necrosis is positively correlated with tumor
depth (F = 0.281, p = 0.002, Spearman-Rho)a n dt u m o r
size (F = 0.355, p < 0.001, Spearman-Rho).
Tumor size
There was no correlation between tumor size and maxi-
mum extent of edema (F = 0.094, p = 0.303, Pearson).
In a regression analysis a trend towards a quadratic
regression of tumor area and extent of maximum edema
(R
2 = 0.047, F = 2.56, p = 0.056, Figure 3D) was
observed.
Multifactorial analysis
In a multifactorial analysis (general linear model) of the
variable maximum edema with the uncorrelated factors
age, regional location of tumor and degree of necrosis,
A
E
BC D
F GH 0 123
Figure 1 Examples for two-dimensional measurement and scoring of edema (A-D) and necrosis (E-H).A - D ,s c o r i n go fe d e m a( t 2 - w
-contrast MRI). E-H, scoring of degree of necrosis (t1-w +contrast MRI).
Seidel et al. BMC Cancer 2011, 11:127
http://www.biomedcentral.com/1471-2407/11/127
Page 3 of 8only degree of necrosis had a significant effect (p =
0.022, Table 3). R
2 of this model was 0.794. If necrosis
was replaced by depth of tumor or tumor size, only
depth of tumor showed an effect (p = 0.016; p = 0.332).
This result indicates that the degree of necrosis is the
strongest independent factor influencing extent of
edema.
Discussion
As a principal finding of this analysis the extent of
tumor edema in patients with primary glioblastoma is
not age-related. We conclude that the bad prognosis of
elderly patients compared to younger patients with pri-
mary glioblastoma [13,14] cannot be attributed to more
perifocal edema.
Additionally, it has been suggested that VEGF expres-
sion, which is the major cause of brain tumor edema
[15,16], may be higher in primary glioblastomas in older
patients [11]. On a descriptive radiological level without
VEGF level determination, this notion is not supported
by the data of our study. In contrast to this, it has been
shown for the VEGF antibody, bevacizumab, that older
age may in fact be associated with a better response
[11,17]. Therefore, careful analysis of older patients in
current trials or even separate trials for patients > 65
years will most likely be rewarding.
Interestingly, large tumor size and extensive necrosis,
which some authors linked to bad prognosis in the past
[9,18] were not found to be more frequent in older
patients.
In the multifactorial analysis, presence and extent of
peritumoral edema in primary glioblastoma was asso-
ciated only with depth of tumor or the extent of necro-
sis, implying that edema is the result of severe hypoxia.
This may be regarded as morphological evidence for the
pathophysiological link between hypoxia, hypoxia-indu-
cible factor 1 alpha expression and VEGF-mediated gen-
esis of peritumoral edema [19,20].
Table 2 Characteristics of n = 122 patients (patient age and morphological tumor parameters in MRI)
Age group Age ≥ 65 ys Age >65 ys Age ≥ 55 ys Age 55-69 ys Age ≥ 70 ys
Nr. of patients n = 61 n = 61 n = 42 n = 41 N = 39
Age [years]
Mean 51 72 46 64 75
Standard dev. 8.91 4.64 7.5 4.3 3.7
Maximum edema [mm]
Mean 23.6 21 23.5 22.7 20.6
Standard dev. 11.96 12.96 11 12.4 14.2
Degree of edema
Mean 1.75 1.43 1.67 1.78 1.31
Median 2 1 1.5 2 1
Standard dev. 1.11 1.12 1.07 1.13 1.13
Tumor area [mm
2]
Mean 1344 1285 1411 1271 1258
Standard dev. 814 903 885 858 837
Degree of necrosis [n (in %)]
none 1 (1.6%) 3 (4.9%) 1 (2.4%) 0 3 (7.7%)
<25% 4 (6.6%) 8 (13.1%) 2 (4.8%) 4 (9.8%) 6 (15.4%)
25-50% 13 (21.3%) 13 (21.3%) 11 (26,1%) 8 (19.5%) 7 (17.9%)
>50% 43 (70.5%) 37 (60.7%) 28 (66.7%) 29 (70.7%) 23 (59.0%)
Tumor localisation [n (in %)]
Depth:
Superficial 10 (16.4%) 9 (14.8%) 5 (11.9%) 7 (17.1%) 7 (17.9%)
Deep 51 (83.6%) 52 (85.2%) 37 (88.1%) 34 (82.9%) 32 (82.1%)
Region of brain:
Frontal 22 (36.1%) 13 (21.3%) 16 (38.1%) 10 (24.4%) 9 (23.1%)
Temporal 15 (24.6%) 20 (32.8%) 11 (26.2%) 7 (17.1%) 9 (23.1%)
Central 14 (23.0%) 13 (21.3%) 7 (16.7%) 16 (39.0%) 12 (30.8%)
Parietooccipital 6 (9.8%) 13 (21.3%) 4 (9.5%) 7 (17.1%) 8 (20.5%)
Basal ganglia 3 (4.9%) 2 (3.3%) 3 (7.1%) 1 (2.4%) 1 (2.5%)
Other 1 (1.6%) 0 1 (2.4%) 0 0
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Figure 2 Comparison of different age groups.
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Page 5 of 8Additionally, in univariate analysis, extent of peritu-
moral edema differed between different regions of brain,
possibly related to differences of structure and direction
of white matter tracts. The structure and density of
white matter is known to vary in different regions of
brain, and edema spread tends to be influenced by the
anatomy of white matter tracts [21,22]. Less dense white
matter, e.g. in frontal association fibers, could facilitate
edema spread, whereas denser commisural fibers, e.g. in
the posterior corpus callosum, or projection fibers, e.g.
in the corticospinal tract, may interfere with edema
extension [23]. This effect might have contributed to
our observation of accentuated edema in frontal white
matter compared to less pronounced edema of tumors
of the basal ganglia or the parietoccipital regions.
Tumor size did not appear to linearly correlate with
extent of edema but a trend towards a quadratic rela-
tionship of tumor area to peritumoral edema existed.
This may have been due in part to some very large
tumors that involved most of the surrounding white
matter and exhibited less edema because of the shortage
of “edema substrate”.
The factors tumor size, degree of necrosis and depth
of tumor appeared to be partially correlated with each
other. An interaction between these factors seems logi-
cal, as a larger glioblastoma might inherently have more
extensive necrosis and a higher chance of involving deep
white matter.
Our data are partially in conflict with results of others
that found a correlation between increasing edema (in a
three step scoring system, comparable to our score) and
advanced age in 110 patients. Interestingly, a high pro-
portion of the tumors analysed in this study showed
areas of non-contrast enhancing tumor (65% in a group
ABCD
A frontal B temporal C basal ganglia D parietooccipital
E deep F small G > 50% necrosis H no necrosis
Figure 4 Examples of different degrees of edema: at different localisations. (A) frontal, B) temporal, C) basal ganglia, D) parietooccipital; E)
superficial and F) deep tumor, G) >50% necrotic tumor, H) non-necrotic tumor.
Table 3 Multifactorial analysis of the variable Maximum
edema extent
Factor F-Value p-Value
Age 0.724 0.820
Regional localisation of tumor 0.884 0.508
Degree of necrosis* 3.896 0.022
Depth of tumor* 6.373 0.017
* alternate factors.
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Page 6 of 8<50 ys, 35% in a group > 50 ys) [8]. In this study the
presence of non-contrast enhancing tumor was asso-
ciated with less edema. The contradicting results may
reflect the differences in study populations. Due to the
exclusion criteria, our study was much less likely to
include secondary glioblastoma, which is known to be a
genetically different entity with less VEGF expression,
progressing slowly from non-enhancing tumor and only
developing areas with necrosis and edema later in the
course of disease [24-26].
In newly diagnosed “primary” tumors, Pope et al.
assessed gene expression and reported that tumors with
non-contrast enhancing parts, i.e. morphological signs of
secondary glioblastoma, differ from tumors without
non-contrast enhancing parts. Pro-angiogenic expression
patterns including VEGF-overexpression were present in
typical primary glioblastoma without non-contrast
enhancing parts, whereas tumors with non-contrast
enhancing areas overexpressed genes that were more
suggestive of secondary glioblastoma [27].
The presence of genetic signatures of secondary glio-
blastoma such as mutated isocitrate dehydrogenase 1 is
much higher in younger patients [28]. Thus, the notion
that glioblastoma swith less peritumoral edema are
more frequent in younger patients appears straightfor-
ward, reflecting the higher frequency of genetic patterns
of secondary glioblastoma in this age group. The mean
patient age in [8] is 54.9 years (CI 52.0-57.8), whereas in
our study the mean patient age is 61.4 years (CI 59.06-
63.68). Age composition of study groups appears crucial
for evaluation of morphologic features of glioblastoma,
as the percentage of tumors with clinical evidence or
genetic signatures of secondary glioblastoma will influ-
ence the measured parameters, especially peritumoral
edema.
Conclusion
In conclusion, our study demonstrates that the extent of
peritumoral edema in primary glioblastoma without
relevant non-contrast enhancing tumor tissue is influ-
enced by the degree of necrosis and the position of
tumor in white matter. Age at diagnosis does not deter-
mine the degree of peritumoral edema. Tumor size,
extent of necrosis and depth of tumor partially interact.
For daily clinical practice in older patients with glioblas-
toma, our data do not support enhanced steroid treatment
or differential use of other anti-edema treatments, such as
the antiangiogenic anti-VEGF(R) treatments [29], although
older age in contrast to all other studies may not be a
negative prognostic factor in anti-VEGF treatment [11,17].
However, it might be interesting to evaluate the differen-
tial effects of various anti-edema treatments based on
tumor localisation or degree of necrosis.
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